|Articles|September 19, 2016

ERT eCOA Solution Assists in Migraine Study

ERT has announced that its electronic Clinical Outcome Assessment (eCOA) solution has assisted CoLucid Pharmaceuticals during its Phase III migraine drug study.

ERT has announced that its electronic Clinical Outcome Assessment (eCOA) solution has assisted CoLucid Pharmaceuticals during its Phase III migraine drug study. Patients used the solution to record migraine occurrence and rate headache pain severity as well as other symptoms.

Read the full release here

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

ERT eCOA Solution Assists in Migraine Study

Related Content

PLPS Launches MyClinicalSuite™ to Deliver Faster Clinical Trial Label Turnarounds Without Compromising Quality, Compliance, or Patient Safety

What Clinical Trials Can Learn from the Gig Economy About Payments

How the Line Between Clinical Data and Real-World Evidence Is Blurring

ACT Brief: RBQM Financial Value Quantified, Sponsor-Configurable AI Systems, and Basket Trials for Rare Pediatrics

Quantifying the Net Financial Value of Deploying Risk-Based Quality Management

Trending on Applied Clinical Trials Online

Quantifying the Net Financial Value of Deploying Risk-Based Quality Management

PLPS Launches MyClinicalSuite™ to Deliver Faster Clinical Trial Label Turnarounds Without Compromising Quality, Compliance, or Patient Safety

ACT Brief: RBQM Financial Value Quantified, Sponsor-Configurable AI Systems, and Basket Trials for Rare Pediatrics

ACT Brief: Enterprise Risk Management, Execution Architecture for AI, and Rare Pediatric Regulatory Support

What Clinical Trials Can Learn from the Gig Economy About Payments